Shots:
In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Tagrisso and prepared a curated analysis report for our readers
Tagrisso is indicated for the treatment of non-small-cell lung carcinomas with specific mutations. It is a 3rd generation drug that belongs to the…

Active Ingredient: Nivolumab
Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial
Dosage Form: Injection
Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1)
First Approval: US (22 Dec 2014), EU (19 Jun 2015)
Revenue Analysis of Opdivo
BMS’ Opdivo gives tough competition to other drugs in the…